Value of serum pepsinogen ratio screening for early gastric cancer and precancerous lesions in Youcheng area

Figure 1 Pepsinogen ratio and Helicobacter pylori-positive rates of three groups of patients. A: Pepsinogen ratio of three groups of patients; B: Helicobacter pylori-positive rates of three groups of patients. ^aP < 0.05 and ^bP < 0.01 in the inter-group comparison or in the comparison with benign lesions. PGR: Pepsinogen ratio; GC: Gastric cancer; HP: Helicobacter pylori.

Figure 2 Receiver operating characteristic curves analysis of the effectiveness of pepsinogen ratio and Helicobacter pylori in distinguishing benign lesions from precancerous lesions. A: Receiver operating characteristic (ROC) curves analysis of the effectiveness of pepsinogen ratio in differentiating benign lesions from precancerous lesions (PCLs); B: ROC curves analysis of the effectiveness of Helicobacter pylori in distinguishing benign lesions from PCLs; C: ROC curves analysis of the effectiveness of pepsinogen ratio + Helicobacter pylori in distinguishing benign lesions from PCLs. PGR: Pepsinogen ratio; HP: Helicobacter pylori.

Figure 3 Receiver operating characteristic curves. A: The receiver operating characteristic (ROC) curve of pepsinogen ratio in differentiating precancerous lesions from early gastric cancer (EGC); B: The ROC curve of Helicobacter pylori in distinguishing precancerous lesions from EGC; C: The ROC curve of the combined detection in differentiating precancerous lesions from EGC; D: The ROC curve of pepsinogen ratio in distinguishing benign lesions from EGC; E: The ROC curve of Helicobacter pylori in differentiating benign lesions from EGC; F: The ROC curve of the combined detection in distinguishing benign lesions from EGC. PGR: Pepsinogen ratio; HP: Helicobacter pylori.